老年1型糖尿病患者转换至MiniMed 780G系统的代谢与血管结局:随机单中心研究
本研究为单中心随机对照试验,纳入34例≥65岁、HbA1c<86 mmol/mol(10%)、未使用过该技术的1型糖尿病患者,1:1随机分配至高级混合闭环(AHCL)治疗或对照组,随访12个月。AHCL组血糖管理快速持续改善,目标范围内时间从基线57.4%升至12个月79.7%(p<0.001),无严重低血糖或酮症酸中毒发生。
要点
- AHCL组目标范围内时间从57.4%升至79.7%,组间校正差异15.7%(95%CI 8.6,22.6)。
- HbA1c组间校正差异为-5 mmol/mol(95%CI -9.7,-0.4 mmol/mol)。
- 无严重不良事件、糖尿病酮症酸中毒或严重低血糖发生。
核心结论
- MiniMed 780G系统对长期1型糖尿病且合并症负担高的老年患者血糖管理有效且安全。
- 观察到血管功能改善的非统计学显著数值趋势(p>0.05),需进一步确认。
主要发现
- AHCL组目标范围内时间从基线57.4%升至12个月79.7%(p<0.001)。
- 高血糖指标(高于范围时间及高于范围时间2)下降(名义p<0.001;p<0.001)。
- 低血糖指标(低于范围时间及低于范围时间2)未增加(名义p=0.463;p=1)。
- 组间校正差异支持AHCL:目标范围内时间15.7%(95%CI 8.6,22.6),HbA1c -5 mmol/mol(95%CI -9.7,-0.4 mmol/mol)[-0.46%;-0.89%,-0.04%]。
- 无严重不良事件、糖尿病酮症酸中毒或严重低血糖发生。
关键数值与推荐
- 纳入标准:年龄≥65岁、1型糖尿病、HbA1c<86 mmol/mol(10%)、未使用过该技术。
- 主要终点:基于血糖管理(目标范围内时间);次要结局:血管状态及其他血糖指标。
临床怎么用
- 对于≥65岁、HbA1c<86 mmol/mol(10%)且未使用过该技术的1型糖尿病患者,可考虑转换至MiniMed 780G系统以改善血糖管理。
- 使用过程中未观察到严重低血糖或酮症酸中毒风险增加。
局限性
- 单中心、开放标签设计,结局评估者未设盲。
- 血管功能改善仅为非统计学显著数值趋势(p>0.05),需进一步确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Hybrid closed-loop insulin delivery systems are increasingly regarded as the preferred therapy for type 1 diabetes, although evidence in older adults remains limited. The aim of this randomised study was to evaluate the effectiveness and safety of the MiniMed 780G system in individuals with type 1 diabetes aged ≥65 years, with HbA1c<86 mmol/mol (10%), who were naive to this technology, with the primary endpoint based on glycaemic management (time in range). Vascular status and other glycaemic metrics were assessed as secondary outcomes. METHODS: This single-centre, open labelled (outcome assessors were not masked), randomised, controlled, parallel-group trial enrolled 34 participants who were randomly assigned in a 1:1 ratio using a computer-generated randomisation schedule to either advanced hybrid closed-loop (AHCL) therapy or control therapy (multiple daily injections or continuous subcutaneous insulin infusion) and followed for 12 months. RESULTS: Twenty-nine participants completed the study. Baseline characteristics, including glycaemic metrics, were comparable across groups (p>0.05). The AHCL group demonstrated a rapid and sustained improvement in glycaemic management, with time in range increasing from 57.4% at baseline to 79.7% at 12 months (p<0.001), accompanied by reductions in hyperglycaemia as reflected by time above range and time above range 2 (nominal p<0.001; p<0.001), and with no increase in hypoglycaemia across time below range and time below range 2 (nominal p=0.463; p=1). Adjusted between-group differences favoured AHCL for time in range (15.7% [95% CI 8.6, 22.6]) and HbA1c (-5 mmol/mol; [95% CI -9.7, -0.4 mmol/mol] [-0.46%; -0.89%, -0.04%]). No serious adverse events or episodes of diabetic ketoacidosis or severe hypoglycaemia occurred. Post-occlusive reactive hyperaemia showed a shortening of time to maximal flow in the AHCL group, indicating a favourable numerical trend towards improved microvascular function (nominal p>0.05). Retinal vascular status assessed using artificial intelligence remained stable throughout follow-up in both eyes (nominal p=0.710 and p=0.563, respectively). CONCLUSIONS/INTERPRETATION: The MiniMed 780G system appears effective for glycaemic management and safe for use in older adults with long-standing type 1 diabetes and a high burden of comorbidities. A non-statistically significant numerical tendency (p>0.05) in the improvement of vascular function that requires further confirmation was also observed. TRIAL REGISTRATION: ClinicalTrials.gov NCT06207838.
引用
- Matejko B, Cyranka K, Suduł P, et al. Metabolic and vascular outcomes after transition to the MiniMed 780G system in adults ≥65 years with type 1 diabetes: a randomised, single-centre study. Diabetologia. 2026. PMID: 42347980. doi:10.1007/s00125-026-06780-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。